Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis
Zhaoyan Chen, Fangyuan Tian · 2024
Read Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis by Zhaoyan Chen, Fangyuan Tian (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11671524.txt.
Description
Zhaoyan Chen and Fangyuan Tian weighed in 2024 whether a tweaked drug pair is worth its cost for gallbladder cancer in China. The cancer is among the most common bile duct cancers, and it often can not be cut out. Their economic model built on a trial where the pair, gemcitabine with oxaliplatin, beat an older mix on survival. A Markov model rolled costs and health gains over ten years from a societal view.
The pair added health gains but at a cost per year of good life well above China's pay threshold. The chance it counts as good value at that line was nil. Tweaks to side-effect, test, and hospital costs barely moved the call. The pair is not good value there, they find.
Catalog record
| CREATOR | Zhaoyan Chen, Fangyuan Tian |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |